RESULTS: There was significant improement in the primary endpoint in the 25-mg and 50-mg groups s placebo.
RESULTS: There was significant improement in the primary endpoint in the 25-mg and 50-mg groups s placebo.
结果：在用25毫克和50毫克患者对比安慰剂组中，试验主要终末点之间并无显著改善。